Developing first Glx targeted antidepressant to address suicidality in bipolar depression. Lead candidate, NRX-101 is in Ph 2b/3 development, (Breakthrough Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. Reported Ph 2 efficacy and safety data for NRX-011 in Dec 18, suggesting potential for NRX-101 in maintaining remission from several bipolar depression with acute suicidal ideation following an initial stabilization with ketamine. Co is also leading Relief Therapeutics’ Ph 2 trial of Aviptadil to treat COVID-19 induced ARDS in the US.
US - South Atlantic
Central Nervous System
913 North Market Street
Wilmington, DE 19801
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.